Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on AC Immune SA. The associated price target remains the same with $12.00.

Andrew Fein has given his Buy rating due to a combination of factors that highlight AC Immune SA’s promising advancements in treating Parkinson’s Disease. The company has demonstrated a groundbreaking approach with its active vaccine, ACI-7104, which has shown a 100% responder rate in generating anti-alpha-synuclein antibodies, significantly outperforming placebo results. This vaccine offers a continuous, high-titer surveillance system that surpasses the limitations of passive antibodies, which often struggle with blood-brain barrier penetration and short half-lives.
Moreover, the interim Phase 2 data reveals statistically significant stabilization of neurofilament light chain (NfL) levels, indicating a halt in neuronal death, a critical endpoint in Parkinson’s treatment. The DaT-SPECT imaging results further suggest potential disease modification, as they show trends toward structural preservation in the brain. These findings, coupled with the vaccine’s ability to maintain protein solubility and reduce inflammatory responses, provide a robust data package that not only de-risks the asset but also positions it for accelerated development and potential business interest.